A Phase 1 interventional study of Vorinostat and Lenalidomide in Relapsed or Refractory Multiple Myeloma, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-18.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing vorinostat in Multiple Myeloma — none open to participants now, 1 under way, none of them phase 3. Vorinostat · Multiple Myeloma.
Among the 19 studies testing vorinostat in Multiple Myeloma, this one is the 8th largest by enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2008, is one of 10 in phase 1, and was the 6th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →None of the 19 studies testing vorinostat in Multiple Myeloma is open now. The open studies under Multiple Myeloma, anywhere →
Vorinostat: first FDA approval 2006 (ZOLINZA). What it is approved for, and how studies give it, is on its page →
Of the 586 Multiple Myeloma studies recruiting now, 431 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 8 · Phase 3 1
First in 2000; this study’s year is marked. 5 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 31 is below the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 31 across the 17 interventional studies. Of the 15 that completed or were terminated, 6 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 19 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
20 studies in Multiple Myeloma by Merck & Co., Inc: none open now, 1 under way, none of them phase 3. Of 18 finished, 12 (67%) have results posted.
Among the 20 studies in Multiple Myeloma by Merck & Co., Inc, this one is the 18th largest by enrollment, is one of 3 that started in 2008, is one of 14 in phase 1, and was the 5th registered.
Merck & Co., Inc’s Multiple Myeloma studies by the year they started, since 2000.
1 of the studies testing vorinostat in Multiple Myeloma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01297764Hackensack Meridian HealthA Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing vorinostat in Multiple Myeloma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 20 in Multiple Myeloma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this Phase I study of vorinostat in combination with lenalidomide and dexamethasone in participants with relapsed or refractory multiple myeloma is to determine the maximum tolerated dose (MTD) as estimated by the incidence of dose-limiting toxicities (DLTs) and recommended Phase 2 dose (RP2D) as estimated by the incidence of drug-related adverse events (AEs).
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
This study's enrollment of 31 is below the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Browse Multiple Myeloma studies →Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Compared within Multiple Myeloma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive vorinostat 300 mg orally once-daily (QD) on Days 1-7 and Days 15-21; lenalidomide 10 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.
Drug: Vorinostat · Drug: Lenalidomide · Drug: Dexamethasone
Participants will receive vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 10 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.
Drug: Vorinostat · Drug: Lenalidomide · Drug: Dexamethasone
Participants will receive vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 15 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.
Drug: Vorinostat · Drug: Lenalidomide · Drug: Dexamethasone
Participants will receive vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 20 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.
Drug: Vorinostat · Drug: Lenalidomide · Drug: Dexamethasone
Participants will receive vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 25 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.
Drug: Vorinostat · Drug: Lenalidomide · Drug: Dexamethasone
Vorinostat 300 mg or 400 mg QD via oral capsule on Days 1-7 and Days 15-21 of each 28-day cycle.
Also known as: MK-0683, Suberoylanilide hydroxamic acid, Zolinza
Lenalidomide 10 mg, 15 mg, 20 mg or 25 mg QD via oral capsule on Days 1-21 of each 28-day cycle.
Also known as: Revlimid
Dexamethasone 40 mg QD via oral tablet on Days 1, 8, 15 and 22 of each 28-day cycle.
Also known as: Decadron
Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)
DLTs consisted of hematologic or non-hemtologic toxicities. Hematologic DLT was any grade (gr) 4 neutropenia lasting ≥7 days, gr 4 thrombocytopenia or gr 5 hematologic toxicity. Non-hematologic DLT was any gr 3, 4 or 5 non-hematologic toxicity with the exception of (1) gr 3 nausea, vomiting, diarrhea or dehydration not compliant with medical care, lasting \<48 hours (2) gr 3 acidosis/alkalosis returning to ≤ gr 2 by 48 hours of medical care (3) gr 3 liver function test elevation without symptoms, lasting ≤5 days (4) Gr 3 amylase elevation without symptoms (5) Gr 3 hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia or hyphosphatemia responding to medical care (6) Gr 3 hypercholeresterolemia or hypertriglyceridemia. A drug-related AE causing dose modification of study drug is also considered a DLT. Per protocol DLTs were analyzed in the first 28-day treatment cycle. The number of participants experiencing DLTs is reported here for all participants who got ≥1 dose of study drug.
Time frame: Cycle 1 (Up to 28 days)
Number of Participants Experiencing Drug-Related Adverse Events (AEs)
An AE was defined as any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening of a pre-existing condition which is temporally associated with the use of the Sponsor's product is also an AE. An AE was considered related to a drug as determined by the investigator based on exposure (evidence of exposure to drug), time course (time of AE onset versus drug-induced effect), likely cause (AE etiology related or un-related to drug), de-challenge (drug dose reduction/discontinuation) or re-challenge (drug re-exposure). Per protocol participants experiencing drug-related AEs were analyzed at the time of the protocol-specified final statistical analysis with a 3-September (Sep)-2012 data cut-off. The number of participants experiencing drug-related AEs is reported here for all participants who got ≥1 dose of study drug.
Time frame: Up to ~55 months (through pre-specified final statistical analysis cut-off date of 3-Sep-2012)
Number of Participants Experiencing Best Overall Response Determined by Complete Response (CR), Near Complete Response (NCR), Very Good Partial Response (VGPR), Partial Response (PR), Minimal Response (MR), Stable Disease (SD) or Progressive Disease (PD)
Best overall tumor response consisted of CR (negative M-protein immunofixation \[IF\], \<5% bone marrow \[BM\] plasma cells, no soft tissue plasmacytomas \[STP\]), NCR (positive M-protein IF, \<5% BM plasma cells, no STP), VGPR (≥90% M-protein decrease, \<5% BM plasma cells, no STP), PR (≥50% M-protein, BM plasma cells, STP decrease), MR (25-49% M-protein, BM plasma cells, STP decrease), SD (\<25% decrease-25% increase in M-protein, BM plasma cells; \<25% decrease-increase in definite STP) or PD (≥25% M-protein, BM plasma cells increase; new STP, lesions). Per protocol participants experiencing best overall response by CR, NCR, VGPR, PR, MR, SD or PD were analyzed as a single prespecified analysis at the time of protocol-specified final statistical analysis with a 3-Sep-2012 data cut-off. The number of participants experiencing best overall response by CR, NCR, VGPR, PR, MR, SD or PD is reported here for all participants who got ≥1 dose of study drug and had a post baseline efficacy assessment.
Time frame: Up to ~55 months (through pre-specified final statistical analysis cut-off date of 3-Sep-2012)
| Milestone | Level 1: Vorinostat 300 mg + Lenalidomide 10 mg | Level 2: Vorinostat 400 mg + Lenalidomide 10 mg | Level 3: Vorinostat 400 mg + Lenalidomide 15 mg | Level 4: Vorinostat 400 mg + Lenalidomide 20 mg | Level 5: Vorinostat 400 mg + Lenalidomide 25 mg |
|---|---|---|---|---|---|
| Started | 4 | 4 | 3 | 3 | 17 |
| Completed | 0 | 0 | 0 | 0 | 1 |
| Not completed | 4 | 4 | 3 | 3 | 16 |
| Withdrew: Progressive disease | 3 | 3 | 3 | 3 | 9 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 1 | 1 | 0 | 0 | 6 |
DLTs consisted of hematologic or non-hemtologic toxicities. Hematologic DLT was any grade (gr) 4 neutropenia lasting ≥7 days, gr 4 thrombocytopenia or gr 5 hematologic toxicity. Non-hematologic DLT was any gr 3, 4 or 5 non-hematologic toxicity with the exception of (1) gr 3 nausea, vomiting, diarrhea or dehydration not compliant with medical care, lasting \<48 hours (2) gr 3 acidosis/alkalosis returning to ≤ gr 2 by 48 hours of medical care (3) gr 3 liver function test elevation without symptoms, lasting ≤5 days (4) Gr 3 amylase elevation without symptoms (5) Gr 3 hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia or hyphosphatemia responding to medical care (6) Gr 3 hypercholeresterolemia or hypertriglyceridemia. A drug-related AE causing dose modification of study drug is also considered a DLT. Per protocol DLTs were analyzed in the first 28-day treatment cycle. The number of participants experiencing DLTs is reported here for all participants who got ≥1 dose of study drug.
| Participants | Level 1: Vorinostat 300 mg + Lenalidomide 10 mg | Level 2: Vorinostat 400 mg + Lenalidomide 10 mg | Level 3: Vorinostat 400 mg + Lenalidomide 15 mg | Level 4: Vorinostat 400 mg + Lenalidomide 20 mg | Level 5: Vorinostat 400 mg + Lenalidomide 25 mg |
|---|---|---|---|---|---|
| Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) | 0 | 0 | 0 | 0 | 1 |
An AE was defined as any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening of a pre-existing condition which is temporally associated with the use of the Sponsor's product is also an AE. An AE was considered related to a drug as determined by the investigator based on exposure (evidence of exposure to drug), time course (time of AE onset versus drug-induced effect), likely cause (AE etiology related or un-related to drug), de-challenge (drug dose reduction/discontinuation) or re-challenge (drug re-exposure). Per protocol participants experiencing drug-related AEs were analyzed at the time of the protocol-specified final statistical analysis with a 3-September (Sep)-2012 data cut-off. The number of participants experiencing drug-related AEs is reported here for all participants who got ≥1 dose of study drug.
| Participants | Level 1: Vorinostat 300 mg + Lenalidomide 10 mg | Level 2: Vorinostat 400 mg + Lenalidomide 10 mg | Level 3: Vorinostat 400 mg + Lenalidomide 15 mg | Level 4: Vorinostat 400 mg + Lenalidomide 20 mg | Level 5: Vorinostat 400 mg + Lenalidomide 25 mg |
|---|---|---|---|---|---|
| Number of Participants Experiencing Drug-Related Adverse Events (AEs) | 2 | 3 | 3 | 3 | 17 |
Best overall tumor response consisted of CR (negative M-protein immunofixation \[IF\], \<5% bone marrow \[BM\] plasma cells, no soft tissue plasmacytomas \[STP\]), NCR (positive M-protein IF, \<5% BM plasma cells, no STP), VGPR (≥90% M-protein decrease, \<5% BM plasma cells, no STP), PR (≥50% M-protein, BM plasma cells, STP decrease), MR (25-49% M-protein, BM plasma cells, STP decrease), SD (\<25% decrease-25% increase in M-protein, BM plasma cells; \<25% decrease-increase in definite STP) or PD (≥25% M-protein, BM plasma cells increase; new STP, lesions). Per protocol participants experiencing best overall response by CR, NCR, VGPR, PR, MR, SD or PD were analyzed as a single prespecified analysis at the time of protocol-specified final statistical analysis with a 3-Sep-2012 data cut-off. The number of participants experiencing best overall response by CR, NCR, VGPR, PR, MR, SD or PD is reported here for all participants who got ≥1 dose of study drug and had a post baseline efficacy assessment.
| Participants | Level 1: Vorinostat 300 mg + Lenalidomide 10 mg | Level 2: Vorinostat 400 mg + Lenalidomide 10 mg | Level 3: Vorinostat 400 mg + Lenalidomide 15 mg | Level 4: Vorinostat 400 mg + Lenalidomide 20 mg | Level 5: Vorinostat 400 mg + Lenalidomide 25 mg |
|---|---|---|---|---|---|
| CR | 0 | 0 | 0 | 0 | 1 |
| NCR | 0 | 1 | 0 | 0 | 0 |
| VGPR | 1 | 0 | 0 | 1 | 2 |
| PR | 1 | 1 | 0 | 1 | 5 |
| MR | 0 | 0 | 1 | 0 | 2 |
| SD | 1 | 1 | 1 | 0 | 5 |
| PD | 1 | 1 | 1 | 1 | 1 |
Collected over Up to ~66 months (through database cut-off date of 20-August-2013). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Level 1: Vorinostat 300 mg + Lenalidomide 10 mg | 0/4 (0%) | 2/4 (50%) | 4/4 (100%) |
| Level 2: Vorinostat 400 mg + Lenalidomide 10 mg | 1/4 (25%) | 1/4 (25%) | 4/4 (100%) |
| Level 3: Vorinostat 400 mg + Lenalidomide 15 mg | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Level 4: Vorinostat 400 mg + Lenalidomide 20 mg | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Level 5: Vorinostat 400 mg + Lenalidomide 25 mg | 3/17 (17.6%) | 8/17 (47.1%) | 17/17 (100%) |
| Event | Level 1: Vorinostat 300 mg + Lenalidomide 10 mg | Level 2: Vorinostat 400 mg + Lenalidomide 10 mg | Level 3: Vorinostat 400 mg + Lenalidomide 15 mg | Level 4: Vorinostat 400 mg + Lenalidomide 20 mg | Level 5: Vorinostat 400 mg + Lenalidomide 25 mg |
|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/4 | 0/4 | 0/3 | 1/3 | 1/17 |
| Chest painGeneral disorders | 0/4 | 0/4 | 0/3 | 1/3 | 0/17 |
| Accidental overdoseInjury, poisoning and procedural complications | 0/4 | 0/4 | 1/3 | 0/3 | 0/17 |
| Sternal fractureInjury, poisoning and procedural complications | 0/4 | 0/4 | 0/3 | 1/3 | 0/17 |
| Bronchitis viralInfections and infestations | 1/4 | 0/4 | 0/3 | 0/3 | 0/17 |
| PneumoniaInfections and infestations | 1/4 | 1/4 | 0/3 | 0/3 | 2/17 |
| SepsisInfections and infestations | 0/4 | 1/4 | 0/3 | 0/3 | 0/17 |
| Septic shockInfections and infestations | 1/4 | 0/4 | 0/3 | 0/3 | 0/17 |
| SyncopeNervous system disorders | 1/4 | 0/4 | 0/3 | 0/3 | 0/17 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/4 | 0/4 | 0/3 | 0/3 | 0/17 |
| Event | Level 1: Vorinostat 300 mg + Lenalidomide 10 mg | Level 2: Vorinostat 400 mg + Lenalidomide 10 mg | Level 3: Vorinostat 400 mg + Lenalidomide 15 mg | Level 4: Vorinostat 400 mg + Lenalidomide 20 mg | Level 5: Vorinostat 400 mg + Lenalidomide 25 mg |
|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 4/4 | 1/4 | 1/3 | 3/3 | 9/17 |
| Back painMusculoskeletal and connective tissue disorders | 1/4 | 0/4 | 3/3 | 0/3 | 5/17 |
| DiarrhoeaGastrointestinal disorders | 2/4 | 3/4 | 2/3 | 1/3 | 7/17 |
| Blood magnesium decreasedInvestigations | 3/4 | 0/4 | 1/3 | 2/3 | 2/17 |
| Blood phosphorus decreasedInvestigations | 1/4 | 3/4 | 2/3 | 0/3 | 2/17 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/4 | 2/4 | 1/3 | 1/3 | 7/17 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/4 | 2/4 | 1/3 | 1/3 | 12/17 |
| NeutropeniaBlood and lymphatic system disorders | 2/4 | 2/4 | 1/3 | 2/3 | 6/17 |
| DyspepsiaGastrointestinal disorders | 2/4 | 0/4 | 0/3 | 2/3 | 2/17 |
| PyrexiaGeneral disorders | 0/4 | 2/4 | 2/3 | 0/3 | 4/17 |
| Age, Continuous(Years) | Level 1: Vorinostat 300 mg + Lenalidomide 10 mg | Level 2: Vorinostat 400 mg + Lenalidomide 10 mg | Level 3: Vorinostat 400 mg + Lenalidomide 15 mg | Level 4: Vorinostat 400 mg + Lenalidomide 20 mg | Level 5: Vorinostat 400 mg + Lenalidomide 25 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 69.5 ± 4.7 | 58.5 ± 2.1 | 66.3 ± 6.1 | 55.7 ± 2.5 | 64.1 ± 7.2 | 63.5 ± 7.0 |
| Sex: Female, Male(Participants) | Level 1: Vorinostat 300 mg + Lenalidomide 10 mg | Level 2: Vorinostat 400 mg + Lenalidomide 10 mg | Level 3: Vorinostat 400 mg + Lenalidomide 15 mg | Level 4: Vorinostat 400 mg + Lenalidomide 20 mg | Level 5: Vorinostat 400 mg + Lenalidomide 25 mg | Total |
|---|---|---|---|---|---|---|
| Female | 2 | 1 | 2 | 1 | 7 | 13 |
| Male | 2 | 3 | 1 | 2 | 10 | 18 |
No study locations are listed for this record.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Feb 2008 to primary completion in Sep 2012, 54 months.
Results were first posted in Nov 2020, 8 years 2 months after primary completion.
Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's 54 months is above that.
Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Vorinostat · Lenalidomide · Dexamethasone